Open AccessEndostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review
Author(s) -
Chen Xiao,
Fangye Xu,
Rong Wang,
Qi Liang,
Kai Shen,
Jiali Xu,
Lianke Liu
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s335139
Subject(s) - medicine , apatinib , ovarian cancer , oncology , paclitaxel , bevacizumab , nedaplatin , chemotherapy , debulking , cancer , progression free survival , gefitinib , trabectedin , metastasis , surgery , cisplatin , epidermal growth factor receptor , soft tissue , soft tissue sarcoma
Ovarian cancer (OC) is a common malignancy in the gynecological tumor. Standard treatment for ovarian cancer is surgery and chemotherapy based on paclitaxel and platinum. However, traditional chemotherapy for ovarian cancer is limited by drug resistance and systemic side effects. It is imperative to explore effective treatment options for refractory ovarian cancer.